Holen Sie sich die Stockscreener-App
30.98
2.52%
-0.80
Handel nachbörslich:
30.98
Schlusskurs vom Vortag:
$31.78
Offen:
$31.66
24-Stunden-Volumen:
188.43K
Relative Volume:
0.82
Marktkapitalisierung:
$2.04B
Einnahmen:
$282.04M
Nettoeinkommen (Verlust:
$221.88M
KGV:
9.2043
EPS:
3.3658
Netto-Cashflow:
$-449.57M
1W Leistung:
-0.21%
1M Leistung:
-17.65%
6M Leistung:
+13.31%
1J Leistung:
+15.21%
1-Tages-Spanne:
$30.80
$31.78
1-Wochen-Bereich:
$30.80
$31.85
52-Wochen-Spanne:
$22.36
$37.78
Galapagos Nv Adr Stock (GLPG) Company Profile
Firmenname
Galapagos Nv Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie GLPG mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLPG
Galapagos Nv Adr
|
30.98 | 2.09B | 282.04M | 221.88M | -449.57M | 3.3658 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Galapagos Nv Adr Stock (GLPG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-22 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-08-05 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2025-02-14 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-11-20 | Herabstufung | Kepler | Hold → Reduce |
| 2024-09-09 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-08-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-03-28 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-03-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-08-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-05-05 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-01-23 | Hochstufung | Jefferies | Underperform → Hold |
| 2022-11-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-09-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-27 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-19 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-08-06 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-04-20 | Eingeleitet | Deutsche Bank | Buy |
| 2021-04-14 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-02-23 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-02-19 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-02-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-19 | Eingeleitet | Maxim Group | Buy |
| 2020-10-21 | Herabstufung | Goldman | Neutral → Sell |
| 2020-08-25 | Herabstufung | Jefferies | Buy → Hold |
| 2020-08-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-08-19 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-08-19 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-07-10 | Herabstufung | Stifel | Buy → Hold |
| 2020-03-30 | Hochstufung | Jefferies | Hold → Buy |
| 2020-03-18 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2020-02-25 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2020-02-24 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2020-02-20 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-01-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-12-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-12-17 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-12-13 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-12-02 | Eingeleitet | BofA/Merrill | Neutral |
| 2019-09-09 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-07-31 | Hochstufung | UBS | Neutral → Buy |
| 2019-07-29 | Herabstufung | Jefferies | Buy → Hold |
Alle ansehen
Galapagos Nv Adr Aktie (GLPG) Neueste Nachrichten
Galapagos stock price target raised to $28 from $27 at RBC Capital - Investing.com
Galapagos stock rating upgraded by Leerink Partners on cost-cutting moves - Investing.com
PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Why Crown Holdings Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company’s Ongoing Transformation - GlobeNewswire Inc.
Galapagos Appoints Fred Blakeslee as General Counsel - The Globe and Mail
How Have Insiders Been Trading Winmark Corporation (WINA) Stock? - fostersleader.com
Why You Need Galapagos NV ADR (GLPG) On Your Watchlist - fostersleader.com
Stock on Demand This Week: Hour Loop Inc (HOUR) - fostersleader.com
MasterCraft Boat Holdings Inc (MCFT): What the Financials Tell Us - fostersleader.com
Is Buying Stock In Radiopharm Theranostics Ltd ADR (RADX) A Good Move Today? - fostersleader.com
Major Brokerage Firms Issue Research Notes on Surgepays Inc (SURG) - fostersleader.com
Vishay Precision Group Inc (VPG) Shares: Cheap or Risky? - fostersleader.com
Clene Inc (CLNN): What Technical Indicators Show - fostersleader.com
SolarMax Technology Inc (SMXT): What Does Valuation Ratios Tell Us? - fostersleader.com
Galapagos Updates on Cell Therapy Business Strategic Review - The Globe and Mail
Galapagos (0JXZ) was downgraded to a Sell Rating at Deutsche Bank - The Globe and Mail
Galapagos NV Reports Strong H1 2025 Results Amid Strategic Transformation - The Globe and Mail
Raymond James reiterates Market Perform rating on Galapagos stock - Investing.com
Raymond James reiterates Market Perform rating on Galapagos stock By Investing.com - Investing.com South Africa
Galapagos ADR earnings missed by $0.05, revenue topped estimates - Investing.com
Galapagos stock holds as CEO change, spinoff plans halted By Investing.com - Investing.com India
Galapagos stock holds as CEO change, spinoff plans halted - Investing.com
Ratios in Focus: Analyzing Galapagos NV ADR (GLPG)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Galapagos stock holds Market Perform rating at Raymond James - Investing.com
Galapagos To Spin Off Innovative Medicines Business - Forbes
Galapagos stock downgraded to Reduce on strategic concerns - Investing.com
Why This Rival To Gilead, Novartis Just Jumped 10% — And Why There Are Caveats - Investor's Business Daily
Earnings call: Galapagos focuses on oncology and immunology in H1 2024 report - Investing.com
Galapagos NV shares poised for outperformance, says TD Cowen - Investing.com
Adaptimmune and Galapagos partner on cancer therapy - Investing.com
Earnings call: Galapagos outlines strategic focus in Q1 2024 results - Investing.com
Billionaire hedge fund manager David Einhorn’s portfolio revealed - Daily Investor
+ND Capital's European Investment Strategy Delivers Again as Sale of CellPoint to Galapagos Paves the Way for Disruptive Point-of-Care Cell Therapy Model for Cancer Patients - Barchart.com
GLPG Stock Price and Chart — EURONEXT:GLPG - TradingView
Galapagos Surges On New CEO and Upgrade News - Investing.com
The Daily Biotech Pulse: Amarin Vascepa Data, Galapagos Osteoarthritis Drug Update, 4 IPOs - Yahoo Finance
Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates - Benzinga
The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology - Yahoo Finance
The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher - Benzinga
Galapagos NV (GLPG) Stock Price, Trades & News - GuruFocus
AIM tech shares that broke America - Interactive Investor
Novartis demonstrates commitment to lead immuno-dermatology by in-licensing IL-17C compound for atopic dermatitis - Novartis
GLPG Stock Price and Chart — NASDAQ:GLPG - TradingView
The 5 Best-Performing Non-S&P Stocks of 2015 - Forbes
Finanzdaten der Galapagos Nv Adr-Aktie (GLPG)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):